Folate status and the safety profile of antifolates

被引:38
作者
Calvert, H [1 ]
机构
[1] Newcastle Univ, Dept Oncol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
关键词
D O I
10.1016/S0093-7754(02)70209-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Throughout the history of cancer chemotherapy, the control of drug-related toxicity has been a major concern. Antifolates such as methotrexate also have a reputation for sporadic and unpredictable toxicity. Pre-treatment levels of plasma or red cell folate have not been found to be useful in predicting which patients will develop toxicity. During the phase II development of pemetrexed, the plasma levels of homocysteine and methylmalonic acid were studied as sensitive surrogate markers for folate and vitamin B12 status, respectively. These were found to be strongly correlated with the subsequent development of serious drug-related toxicities (myelosuppression, diarrhea, mucosal toxicity, and infection), suggesting that toxicity was related to relative folate deficiency in some cancer patients. A policy of nutritional supplementation was introduced and led to a marked reduction in toxicity and the abolition of treatment-related deaths with apparent preservation of anticancer activity. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 34 条
[1]  
Alati T, 1996, CANCER RES, V56, P2331
[2]  
BARNARD ROBERT D., 1954, AMER JOUR DIGEST DIS, V21, P163, DOI 10.1007/BF02883849
[3]  
BUNN P, 2001, P AN M AM SOC CLIN, V20, pA76
[4]   A PHASE-I EVALUATION OF THE QUINAZOLINE ANTIFOLATE THYMIDYLATE SYNTHASE INHIBITOR, N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID, CB3717 [J].
CALVERT, AH ;
ALISON, DL ;
HARLAND, SJ ;
ROBINSON, BA ;
JACKMAN, AL ;
JONES, TR ;
NEWELL, DR ;
SIDDIK, ZH ;
WILTSHAW, E ;
MCELWAIN, TJ ;
SMITH, IE ;
HARRAP, KR .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (08) :1245-1252
[5]  
Calvert H, 1999, SEMIN ONCOL, V26, P105
[6]   PHASE-II STUDY OF THE ANTIFOLATE N-10-PROPARGYL-5,8-DIDEAZAFOLIC ACID (CB-3717) IN ADVANCED BREAST-CANCER [J].
CANTWELL, BMJ ;
MACAULAY, V ;
HARRIS, AL ;
KAYE, SB ;
SMITH, IE ;
MILSTED, RAV ;
CALVERT, AH .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04) :733-736
[7]  
CELIO L, 2001, P AN M AM SOC CLIN, V20, pA166
[8]   Phase I trial of ZDI694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors [J].
Clarke, SJ ;
Hanwell, J ;
deBeer, M ;
Planting, A ;
VerweiJ, J ;
Walker, M ;
Smith, R ;
Jackman, AL ;
Hughes, LR ;
Harrap, KR ;
Kennealey, GT ;
Judson, IR .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1495-1503
[9]   Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer [J].
Cunningham, D ;
Zalcberg, JR ;
Rath, U ;
Oliver, I ;
vanCutsem, E ;
Svensson, C ;
Seitz, JF ;
Harper, P ;
Kerr, D ;
PerezManga, G .
ANNALS OF ONCOLOGY, 1996, 7 (09) :961-965
[10]   TEMPORARY REMISSIONS IN ACUTE LEUKEMIA IN CHILDREN PRODUCED BY FOLIC ACID ANTAGONIST, 4-AMINOPTEROYL-GLUTAMIC ACID (AMINOPTERIN) [J].
FARBER, S ;
DIAMOND, LK ;
MERCER, RD ;
SYLVESTER, RF ;
WOLFF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1948, 238 (23) :787-793